1400. Treatment of HIV and Use of HAART in HIV Infected Patients with Acute Septic Shock
Session: Poster Abstract Session: HIV: Antiretroviral Therapy
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • Polk1400.pdf (734.1 kB)
  • Background: For HIV patients admitted with sepsis, ARVs are often stopped or held due to myriad concerns including drug interactions, acute renal failure, gastrointestinal dysfunction, or inability to administer crushed medications down feeding tubes. We seek to examine prescription patterns of HAART for HIV positive patients admitted for sepsis in our healthcare system and the impact of HAART prescription on patient outcomes.

    Methods: We identified HIV positive patients from an institutional database of patients admitted for sepsis within our multi-hospital healthcare system and retrospectively extracted further clinical patient and laboratory information as well as information on HAART prescription by chart review. The impact of HAART prescription and immunologic and virologic parameters of HIV infection on mortality was examined.

    Results: Inpatient mortality was 35% in HIV patients admitted for sepsis, compared to 17% for all patients with sepsis in our healthcare system. Opportunistic infections were identified in only 25% of patients while 56% had other infections identified. Only 55% of patients had HAART prescribed while inpatient. CD4 count, virologic suppression, APACHE score, presence of an opportunistic infection, admission to a tertiary care hospital, and inpatient prescription of HAART were all predictors of survival.

    Table: Factors impacting mortality in HIV patients with sepsis in univariate analysis.

    Survivors (n=50)

    Deaths (n=28)

    Odds ratio of survival (p value)

    Mean baseline CD4 count

    309

    64

    (p<0.01)

    Virologic suppression (VL<200)

    48% (n=21 of 44)

    22% (n=5 of 23)

    3.3 (p<0.05)

    Mean APACHE score

    67 (n=32)

    110 (n=17)

    (p<0.01)

    Opportunistic infection

    18% (n=9)

    39% (n=11)

    0.34 (p<0.05)

    Tertiary hospital admission

    50% (n=25)

    21% (n=6)

    3.7 (p<0.05)

    Inpatient HAART prescription

    68% (n=34)

    32% (n=9)

    4.5 (p<0.01)

    In a multivariable analysis both CD4 count and inpatient HAART prescription predicted survival in our cohort with an odds ratio of survival of 3.3 for patients prescribed HAART inpatient compared to their untreated peers.

    Conclusion: Immunologic and virologic status at time of admission predicted survival in HIV patients admitted for sepsis but prescription of HAART to HIV patients admitted for sepsis may increase survival.

    Christopher Polk, MD1, Samuel Webb, MD2, Nigel Rozario, MS3, Charity Moore, PhD3 and Michael Leonard, MD1, (1)Infectious Diseases, Carolinas Healthcare System, Charlotte, NC, (2)Carolinas Healthcare System, Charlotte, NC, (3)Dickson Advanced Analytics, Charlotte, NC

    Disclosures:

    C. Polk, Gilead Sciences: Investigator , Research support
    Viiv Healthcare: Investigator , Research support

    S. Webb, None

    N. Rozario, None

    C. Moore, None

    M. Leonard, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.